JP2024545887A - 安定した受容体アゴニストの医薬組成物、製造方法及びその応用 - Google Patents

安定した受容体アゴニストの医薬組成物、製造方法及びその応用 Download PDF

Info

Publication number
JP2024545887A
JP2024545887A JP2024536467A JP2024536467A JP2024545887A JP 2024545887 A JP2024545887 A JP 2024545887A JP 2024536467 A JP2024536467 A JP 2024536467A JP 2024536467 A JP2024536467 A JP 2024536467A JP 2024545887 A JP2024545887 A JP 2024545887A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
buffer
active ingredient
adjusting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545887A5 (https=
Inventor
リー ドン
イエン ハン
ハオファ ハオ
ジン ユ
ヤン ソン
Original Assignee
ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド filed Critical ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド
Publication of JP2024545887A publication Critical patent/JP2024545887A/ja
Publication of JP2024545887A5 publication Critical patent/JP2024545887A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024536467A 2022-01-10 2023-01-09 安定した受容体アゴニストの医薬組成物、製造方法及びその応用 Pending JP2024545887A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210021736.1 2022-01-10
CN202210021736 2022-01-10
PCT/CN2023/071277 WO2023131325A1 (zh) 2022-01-10 2023-01-09 一种稳定的受体激动剂的药物组合物、制备方法及其应用

Publications (2)

Publication Number Publication Date
JP2024545887A true JP2024545887A (ja) 2024-12-13
JP2024545887A5 JP2024545887A5 (https=) 2026-01-22

Family

ID=87073306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536467A Pending JP2024545887A (ja) 2022-01-10 2023-01-09 安定した受容体アゴニストの医薬組成物、製造方法及びその応用

Country Status (10)

Country Link
US (1) US20250170218A1 (https=)
EP (1) EP4464331A4 (https=)
JP (1) JP2024545887A (https=)
KR (1) KR20240135785A (https=)
CN (1) CN118488848A (https=)
AU (1) AU2023205290A1 (https=)
CA (1) CA3242599A1 (https=)
MX (1) MX2024007861A (https=)
TW (1) TW202333775A (https=)
WO (1) WO2023131325A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102664B2 (en) * 2023-12-27 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating endocrine diseases and disorders
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
WO2025191149A1 (en) * 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
WO2026007980A1 (zh) * 2024-07-03 2026-01-08 上海海雁医药科技有限公司 一种mor受体激动剂的液体组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366692A (zh) * 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
AU2013205144B2 (en) * 2008-06-17 2015-07-16 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN113383014B (zh) * 2019-11-15 2024-06-18 江苏豪森药业集团有限公司 双受体重激动剂化合物及其药物组合物
EP4110800A1 (en) * 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用

Also Published As

Publication number Publication date
CN118488848A (zh) 2024-08-13
EP4464331A4 (en) 2025-05-07
CA3242599A1 (en) 2023-07-13
US20250170218A1 (en) 2025-05-29
MX2024007861A (es) 2024-07-09
TW202333775A (zh) 2023-09-01
AU2023205290A1 (en) 2024-07-11
WO2023131325A1 (zh) 2023-07-13
KR20240135785A (ko) 2024-09-12
EP4464331A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
JP2024545887A (ja) 安定した受容体アゴニストの医薬組成物、製造方法及びその応用
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
JP7060589B2 (ja) ポリエチレングリコールロキセナチドを含有する薬物製剤及びその製造方法
EP3295952B1 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
JP2024545887A5 (https=)
CN1498113A (zh) 稳定性提高的无锌或低锌胰岛素制剂
JP2005537232A (ja) アミリンアゴニストペプチドの製剤
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
CN101095942B (zh) 一种包含稳定剂的Exendin-4注射剂药物配方
KR20230098144A (ko) 당뇨병을 치료하기 위한 이온성 액체 제형
JP2014520112A (ja) ゲル組成物
US12343383B2 (en) High concentration insulin formulation
TW200950784A (en) Treatment for ocular-related disorders
WO2026013454A1 (en) Multi-dose pen of tirzepatide
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
WO2025190304A1 (zh) 包含glp-1和gip双受体激动剂的药物组合物及其用途
WO2026083250A1 (en) Article of manufacture for semaglutide compositions
CN106924723B (zh) 经口腔黏膜给药的含人胰高血糖素样肽-1类似物的药物组合物
HK40000201B (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN115300639A (zh) 一种含有德谷胰岛素的缓释药物组合物及其制备方法
HK40000201A (en) Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260109